Show simple item record

MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+advanced breast cancer (ABC)

dc.contributor.authorTolaney, SM
dc.contributor.authorWardley, Andrew M
dc.contributor.authorZambelli, S
dc.contributor.authorHilton, J
dc.contributor.authorTroso-Sandoval, T
dc.contributor.authorRicci, F
dc.contributor.authorIm, SA
dc.contributor.authorKim, SB
dc.contributor.authorJohnston, SRD
dc.contributor.authorChan, A
dc.contributor.authorGoel, S
dc.contributor.authorCatron, K
dc.contributor.authorYang, Z
dc.contributor.authorGainford, C
dc.contributor.authorAndre, F
dc.date.accessioned2019-12-09T17:23:31Z
dc.date.available2019-12-09T17:23:31Z
dc.date.issued2019en
dc.identifier.citationTolaney SM, Wardley AM, Zambelli S, Hilton J, Troso-Sandoval T, Ricci F, et al. LBA23MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC). Annals of Oncology. 2019;30(Supplement_5):861.en
dc.identifier.doi10.1093/annonc/mdz394.012en
dc.identifier.urihttp://hdl.handle.net/10541/622596
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdz394.012en
dc.titleMonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+advanced breast cancer (ABC)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMedical Oncology, Dana Farber Cancer Institute, Boston, MAen
dc.identifier.journalAnnals of Oncologyen
refterms.dateFOA2020-01-21T20:20:49Z


Files in this item

Thumbnail
Name:
mdz394.012.pdf
Size:
84.27Kb
Format:
PDF
Description:
From UNPAYWALL. Conference abstract
Download

This item appears in the following Collection(s)

Show simple item record